A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs AMP 514 (Primary) ; Durvalumab
- Indications Renal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 01 Feb 2018 Planned End Date changed from 29 Jan 2021 to 26 Feb 2021.
- 01 Feb 2018 Planned primary completion date changed from 29 Jan 2021 to 26 Feb 2021.
- 11 Jul 2017 Planned End Date changed from 8 Jul 2019 to 29 Jan 2021.